Latest Medicine stories from Life.
In recent biotech developments, Novartis has reaffirmed its focus on molecular glue strategies amidst rising drug costs for seniors and advancements in leukemia treatments.
Elizabeth Selvin reflects on the stark contrast in publication fees at Nature Medicine between 2025 and 2026, highlighting a significant financial burden for researchers.
A recent analysis highlights a troubling increase in drug shortages and pricing pressures in Europe, with U.S. authorities intensifying their scrutiny.
As the U.S. observes the situation, European countries are developing varied approaches to drug pricing, which could have significant implications for the pharmaceutical sector and patient access.
Novo Nordisk expresses disappointment with a drug it previously contested with Pfizer. Meanwhile, Revolution and Tango show encouraging cancer results, and Incyte acquires a bleeding disorder treatment.
Lilly has released additional data regarding the safety and tolerability of its obesity drug retatrutide, contributing to ongoing discussions in the pharmaceutical sector.
Recent findings suggest that while Boehringer Ingelheim’s obesity drug may effectively reduce liver fat, its overall weight loss results are less compelling.
The American Diabetes Association's annual conference in New Orleans showcased new insights, including developments in hormone receptors and a monthly obesity drug.
Recent findings from a midstage study indicate that Pfizer's obesity treatment, obtained from Metsera, may be effective with monthly dosing.
The recent cancellation of medical entrance tests affecting over 2 million candidates has ignited frustration towards Prime Minister Narendra Modi's administration.
RevMed's cancer treatment appears inaccessible for certain patients, while the Supreme Court maintains an essential pathway for generic drugs amid ongoing biotech developments.
As we reflect on the six-year mark since the onset of the COVID-19 pandemic, experts are evaluating how coordinated responses to domestic violence have evolved during this challenging period.
A recent presentation on Revolution Medicines' pancreatic cancer drug garnered significant attention, earning a standing ovation. However, the broader biotech sector faced challenges this week.
Despite not yet receiving approval, Revolution Medicines' pancreatic cancer drug is already the subject of discussions regarding its potential expanded applications.
NewLimit, a longevity-focused startup, has successfully raised $435 million in funding, which will support its first clinical trial targeting liver medicine.
As states increase scrutiny on corporate medicine, the telehealth sector faces significant challenges. The focus is on the corporate frameworks that support direct-to-consumer services.
Ivonescimab, a lung cancer treatment from China, garnered attention at ASCO for its potential to extend survival in patients with squamous cell lung cancer, though experts urge for trials involving a more diverse patient base.
A new study indicates that initiating hormone therapy before surgery may lead to lower relapse rates in prostate cancer patients, suggesting a shift in treatment strategies.
Recent findings presented at ASCO indicate significant progress in targeting a key component of pancreatic cancer, referred to as a 'greasy ball'.
Mark Goldsmith, CEO of Revolution Medicines, has announced the upcoming submission of daraxonrasib for FDA approval as the company begins shipping the experimental drug.